Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC

Chemotherapeutic agents exert significant immunomodulatory effects by influencing tumor-infiltrating immune cells. However, the sequence and combination of chemotherapy regimens differentially modulate immune cell dynamics, ultimately impacting treatment efficacy and patient survival. Glutathione, a critical bioactive molecule, demonstrates broad potential in tumor immunotherapy. Through mechanisms such as scavenging free radicals, modulating immune cell proliferation and differentiation, and regulating cytokine expression, glutathione achieves precise modulation of immune responses to enhance immune system functionality. To investigate whether glutathione can enhance the clinical efficacy of current chemo-immunotherapy regimens in non-small cell lung cancer (NSCLC), investigators conducted this clinical study.

NCT Number	NCT06896422
Lead Sponsor	The First Affiliated Hospital of Zhengzhou University
Conditions	Non-Small Cell Lung Cancer, Chemotherapy, PD1 Antibody, Glutathione
Enrollment	80 participants
Start Date	2025-06-01
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-08-07